Glaucoma Surgery Devices Global Market Report 2024

The glaucoma surgery devices market has grown rapidly in recent years. It will grow from $1.73 billion in 2023 to $1.95 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The expansion observed in the historical period can be ascribed to factors such as the aging population, heightened incidence of glaucoma, augmented awareness, and screening initiatives, advancements in healthcare infrastructure, and the implementation of insurance coverage and reimbursement policies.

The glaucoma surgery devices market is expected to see rapid growth in the next few years. It will grow to $3.25 billion in 2028 at a compound annual growth rate (CAGR) of 13.7%. The anticipated expansion in the forecast period can be credited to factors such as the rising global geriatric population, increased healthcare awareness, collaborative efforts in research and development, the worldwide extension of healthcare services, and a preference among patients for outpatient procedures. Prominent trends expected in the forecast period encompass decentralization and grid resilience, the regulatory landscape, technological advancements, integration with renewables, and environmental considerations.

The expected rise in glaucoma prevalence is anticipated to foster the growth of the glaucoma surgery devices market. Glaucoma, a progressive eye disease, poses a risk to the optic nerve, potentially leading to irreversible vision loss without prompt diagnosis and treatment. The pivotal role of glaucoma surgery devices in executing glaucoma surgeries has enhanced safety, effectiveness, and invasiveness reduction, contributing significantly to the growing demand. According to information shared by the World Glaucoma Association (WGA), an independent organization based in the Netherlands focusing on glaucoma science and care, recent census and prevalence estimates indicate that 79.6 million people were affected by glaucoma in 2020. The projected figure for 2040 suggests an increase to 111.8 million people worldwide, with over 11 million individuals (13% of cases) expected to be bilaterally blind due to glaucoma in 2020. Thus, the upsurge in glaucoma prevalence is poised to propel the glaucoma surgery devices market.

The surge in investments in healthcare infrastructure is projected to drive the growth of the glaucoma surgery devices market in the foreseeable future. Healthcare infrastructure, encompassing physical and organizational structures, resources, and facilities for healthcare service delivery, forms a crucial framework for the effective utilization of glaucoma surgery devices. This enhances patient outcomes and overall efficiency in managing glaucoma. As an illustration, in March 2022, the Department of Health and Aged Care, a governmental organization in Australia overseeing health research and services, announced record spending commitments. The recently elected Coalition Government pledged $132 billion in 2022-2023 and an additional $140 billion in 2025-2026 for healthcare infrastructure, totaling $537 billion over the next four years. Consequently, the increasing investments in healthcare infrastructure are steering the glaucoma surgery device market.

Technological advancements represent a prominent trend gaining traction in the glaucoma surgery devices market. Leading companies in this market are dedicating efforts to developing innovative technologies to maintain their competitive positions. For example, in August 2022, Sight Sciences Inc., a US-based eyecare technology company, introduced the SION Surgical Instrument, the initial bladeless device for goniotomy. This novel Minimally Invasive Glaucoma Surgery (MIGS) device, which does not require implants, is designed to offer a consistent and controlled approach to goniotomy, potentially enhancing outcomes for glaucoma patients. The technology employs a flexible catheter to create micro-incisions in the trabecular meshwork without using a blade, aiming to increase safety and ease of use by eliminating the need to navigate sharp instruments around the eye's anterior chamber and iridocorneal angle.

Major players in the glaucoma surgery devices market are opting for strategic partnerships to expedite the development and launch of iSTAR Medical's MINIject, an innovative MIGS tool for glaucoma patients. This collaborative strategy involves companies leveraging each other's strengths and resources for mutual benefits. In July 2022, AbbVie Inc., a US-based pharmaceutical company, announced a partnership with iSTAR Medical SA. This collaboration enables iSTAR Medical to receive support in the development and promotion of MINIject, while AbbVie expands its glaucoma portfolio, which currently includes stents, sustained-release implants, and drops. The partnership reflects AbbVie's commitment to innovation in glaucoma treatment using interventional techniques. iSTAR Medical SA is a Belgium-based medical technology manufacturer.

In October 2022, Alcon, a Switzerland-based ophthalmology company, completed the acquisition of Ivantis Inc. for an undisclosed amount. The acquisition aimed to enhance Alcon's global surgical portfolio by incorporating the hydrus microstent, a minimally invasive device for treating patients with mild-to-moderate primary open-angle glaucoma. Ivantis is a US-based technology company specializing in the development of minimally invasive glaucoma surgery (MIGS) devices, including the hydrus microstent, designed to restore normal fluid flow in the eye and reduce intraocular pressure.

Major companies operating in the glaucoma surgery devices market report are Alcon, Johnson & Johnson, Abbott Laboratorie, Carl Zeiss Meditec AG, Bausch & Lomb Inc., Topcon Corporation, HAAG-Streit Holding AG, Essilor International S.A., Hoya Corporation, Sonomed Escalon, Iridex Corporation Ltd., Ellex Medical Lasers Ltd., Ziemer Ophthalmic Systems AG, Katalyst Surgical, Nidek Co. Ltd., AbbVie Inc., BVI, Glaukos Corporation, Alievio Inc., Assenti LLC, Avisi Technologies LLC, Chongqing Migos Medical Technology Co Ltd., OcuTherix Inc., OPKO Health Inc., OptoLight Vision Technology, Rheon Medical SA, Sight Sciences Inc., Lumenis Ltd.

North America was the largest region in the glaucoma surgery devices market in 2023. The regions covered in the glaucoma surgery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glaucoma surgery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of glaucoma surgery devices include drainage systems, laser-based devices, implants, and others, serving to address both open-angle and closed-angle glaucoma. Drainage systems involve catheters strategically positioned near the surgical site to evacuate any accumulated blood, pus, or fluid, preventing the buildup within the body. Various surgical techniques fall under this category, such as angle closure glaucoma surgery, aqueous shunt surgery, laser surgery, among others. Drainage systems, facilitating the removal of fluids, find application in diverse contexts, spanning conventional glaucoma surgeries to minimally invasive glaucoma surgeries. These devices cater to different end-users, including eye hospitals, ophthalmology clinics, and outpatient surgical centers.

The glaucoma surgery devices market research report provides glaucoma surgery devices market statistics, including glaucoma surgery devices industry global market size, regional shares, competitors with a glaucoma surgery devices market share, detailed glaucoma surgery devices market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma surgery devices industry. This glaucoma surgery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glaucoma surgery devices market consists of sales ultrasound equipment, tube shunt, and aqueous shunts that help to perform glaucoma surgeries. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.